Reporting of Breast Cancer Do s and Don ts
|
|
- Gloria Wiggins
- 5 years ago
- Views:
Transcription
1 Reporting of Breast Cancer Do s and Don ts 7 th SGH Annual Breast Pathology Course Professor Michael Bilous Conjoint Professor Western Sydney University Consultant Pathologist, Australian Clinical Labs, Sydney 1
2 The Role of the Breast Pathologist Information required from pathology: Prognostic and Predictive factors 1. Local Control margin status 2. Extent of Spread lymph nodes 3. Factors to determine optimal therapy
3 The Role of the Breast Pathologist Information required from pathology: Prognostic and Predictive factors 1. Local Control margin status 2. Extent of Spread lymph nodes 3. Factors to determine optimal therapy
4 How is breast cancer pathology determining therapy? An Historical Perspective Early detection of breast cancer via education, awareness and screening programs has meant that most breast cancers in developed nations are detected early i.e. <50mm, without distant metastases.
5 How is breast cancer pathology determining therapy? Adjuvant chemotherapy for early breast cancer has been effective. Patients are selected on the basis of pathology features such as tumour size and grade, and axillary lymph node status.
6 How is breast cancer pathology determining therapy? Additional biological markers such as ER/PR and HER2 have allowed more targeted treatment (endocrine and anti-her2) Personalised Medicine There was no test which will determine whether an individual patient will benefit from chemotherapy. This results in overtreatment of some and undertreatment of others.
7 How is breast cancer pathology determining therapy? The Human Genome Project enabled the identification of genes in breast cancer that could assist in finding those cancers that have an intrinsic poor prognosis for which adjuvant chemotherapy is indicated: The Gene Expression Profile of the cancer. There is increasing interest in these molecular tests that can more accurately predict the response of a cancer to targeted therapy
8 Pathology Reporting of Breast Cancer Traditional Pathology Molecular Markers Gene Expression Tumour size and grade ER, PR, HER2 Oncotype DX Tumour type Ki-67 MammaPrint Margin status EndoPredict Lymph node status Prosigna LVI Breast Cancer Index {TIL s} Mammostrat etc Prognostic Indices Nottingham Prognostic Index Adjuvant! On line St Gallen 2015 (surrogate intrinsic classification)
9 Pathology Reporting of Breast Cancer Traditional Pathology Molecular Markers Gene Expression Tumour size and grade ER, PR, HER2 Oncotype DX Tumour type Ki-67 MammaPrint Margin status EndoPredict Lymph node status Prosigna LVI Breast Cancer Index {TIL s} Mammostrat etc Prognostic Indices Nottingham Prognostic Index Adjuvant! On line St Gallen 2015 (surrogate intrinsic classification)
10 Invasive Carcinoma Traditional Pathology: Size Type Histological Grade Margin Status Lymph Node (Sentinel Node) status Lymphovascular invasion Changes in adjacent breast tissue All reported according to published Guidelines
11 Size Single greatest dimension in mm assessed by microscopy or macroscopically or in three dimensions For invasive carcinoma, include any DCIS within the tumour but - If DCIS extends outside the invasive carcinoma then 2 measurements are required whole tumour and invasive component For small carcinomas a small increase in size equates to a marked change in predicted ALN status
12 Size of invasive ca DCIS Invasive ca Size of whole lesion
13
14
15 >5mm
16 Type of invasive carcinoma Special types pure tubular, invasive cribriform, tubulo-lobular and mucinous have an excellent prognosis: 1500 patients, 10 years follow-up >80% 10 year survival Ellis et al Histopathol 1992;20:
17 Type of invasive carcinoma Invasive lobular has a slightly better prognosis than invasive duct NST but this varies with subtype: Classical 60% 10 year survival Mixed 55% 10 year survival Pleomorphic 40% 10 year survival Tubulo-lobular 80% 10 year survival
18
19
20 Grade For all invasive carcinomas grading assesses growth pattern and cytological features Elston and Ellis system: Tubules 1-3 Nuclear grade 1-3 Mitoses 1-3 Grade 1 (3-5) Grade 2 (6-7) Grade 3 (8-9) This grading system replaced the Bloom and Richardson system devised ~10 years earlier
21 Grade Reproducibility (kappa statistic) tubules 0.64 nuclear grade 0.4 mitoses 0.52 Ellis et al. Human Pathol. 1981;12:3-4
22
23
24 Margin status Breast tissue is irregular and crumbly There is a large surface area to sample Margin Assessment is an Imperfect Science
25 Lymphovascular invasion Correlates with ALN involvement and early recurrence in ALN negative patients Predictor of long term survival and local recurrence after breast conservation and radiation therapy Rosen Pathol Annu 1983;18: Pinder et al Histopathol 1994;24:41-47
26 Lymphovascular invasion Caution Retraction Artefact Always assess LVI at the advancing edge of the carcinoma Look for clues to identify the lymphatics ie. small vein and arteriole +/- nerve Dermal LVI has greater significance than LVI within the breast tissue
27
28 Gene Expression Profiles - new breast cancer classification- PAGE 28
29 78 carcinomas, 3 benign tumours, 4 normal breast tumours 476 gene chip selected from previous study of 1753 genes Gene clusters: C HER2 associated genes D Novel set unknown function E Basal epithelium and myoepithelium of breast F Normal breast G Luminal cells of breast (ER+) INTRINSIC MOLECULAR SUBTYPES Perou CM, et al. Nature 2000; 406: ; Sorlie T, et al. Proc Natl Acad Sci USA 2003; 100:
30 Prognosis according to genetic profile note luminal B and C merged Perou CM, et al. Nature 2000; 406: ; Sorlie T, et al. Proc Natl Acad Sci USA 2003; 100:
31 Treatment-oriented Molecular Subtypes of breast cancer What the Medical Oncologist wants to know!
32 How do we best use the cancer specimen to supply this information? By using a molecular test? or By using a combination of traditional pathology and immunohistochemistry?
33 Prognosis according to genetic profile note luminal B and C merged Can we identify INTRINSIC Subtypes by Immunohistochemistry? Perou CM, et al. Nature 2000; 406: ; Sorlie T, et al. Proc Natl Acad Sci USA 2003; 100:
34 Pathology Reporting of Breast Cancer Traditional Pathology Molecular Markers Gene Expression Tumour size and grade ER, PR, HER2 Oncotype DX Tumour type Ki-67 MammaPrint Margin status EndoPredict Lymph node status Prosigna LVI Breast Cancer Index {TIL s} Mammostrat etc Prognostic Indices Nottingham Prognostic Index Adjuvant! On line St Gallen 2015 (surrogate intrinsic classification)
35 Gene profiles and pathology Basic Immunohistochemistry and H&E sections can help identify the main intrinsic cancers (not Luminal A or B) Frequency Luminal A cytokeratin 8/18 positive; 50% ER and/or PR+; HER2 - Luminal B cytokeratin 8/18 positive; 20% ER and/or PR+; HER2 +/- Basal-like ER-,PR-,HER2-, HER1+ 15% and/or cytokeratin 5/6 + HER2 enriched HER2 +, ER- 15% Millikan et al Breast Cancer Res Treat 2007 Schnitt et al Int J Surg Pathol 2010
36 Gene profiles and pathology Basic Immunohistochemistry and H&E sections can help identify the main intrinsic cancers (not Luminal A or B) Frequency Luminal A cytokeratin 8/18 positive; 50% ER and/or PR+; HER2 - Luminal B cytokeratin 8/18 positive; 20% ER and/or PR+; HER2 +/- Basal-like ER-,PR-,HER2-, HER1+ 15% and/or cytokeratin 5/6 + HER2 enriched HER2 +, ER- 15% Millikan et al Breast Cancer Res Treat 2007 Schnitt et al Int J Surg Pathol 2010
37 How can we separate Luminal A and B cancers?
38 St Gallen Consensus May 4 th 2015 Coates AS, et al. Ann Oncol 2015; 00: 1 14.
39 St Gallen Consensus May 4 th 2015 Coates AS, et al. Ann Oncol 2015; 00: 1 14.
40 Prognosis according to genetic profile note luminal B and C merged Ki-67 ASSESSMENT Perou CM, et al. Nature 2000; 406: ; Sorlie T, et al. Proc Natl Acad Sci USA 2003; 100:
41 Dowsett M, et al. J Natl Cancer Inst 2011; 103:
42 Ki-67 assessment Core biopsies/tma or surgical excisions 3+ hpf fields selected at the edge of the carcinoma Include any clear hot spots Staining intensity is not relevant Count at least 500 and preferably 1000 cells Express the result as a percentage Cut points?? Apply only if local practice validated against studies with defined cut offs Dowsett M, et al. J Natl Cancer Inst 2011; 103:
43 Ki-67 and breast cancer Problem for the pathologist What threshold to use? 10%, 13%, 20% 25%...other? St Gallen 2015 Laboratory validation, median value used
44 Variable levels of Ki-67 staining; different score in different areas; take average across the whole section
45 Well fixed Poorly fixed
46 Validating Ki-67 scoring in my laboratory Record the Ki-67 score for all cases in which the ER and PR result is >50%; HER2 negative. 2 years counted Median Ki-67 score is 15% Luminal A-like Ki-67 score <5% Luminal B-like Ki-67 score is >25% Intermediate Ki-67 score is 6 25%
47 Maisonneuve P, et al. Br Cancer Res 2014; 16: R65
48 Prognosis according to genetic profile note luminal B and C merged ER/PR expression Perou CM, et al. Nature 2000; 406: ; Sorlie T, et al. Proc Natl Acad Sci USA 2003; 100:
49 Defining molecular subtypes by quantitative receptor (HR) expression 1557 cases; ER/PR/HER2 centrally tested by IHC and RT-qPCR Intrinsic subtype determined by PAM50 Cheang MCU, et al. The Oncologist 2015;20:
50 Defining molecular subtypes by quantitative receptor (HR) expression 283 IHC HER2-ve tumours; HR<1% 73% basal-like; 17% HER2+ve by PAM50 39 IHC HER2-ve tumours; HR 1-9% 44% luminal A/B; 31% HER2+ve; 18% basal-like by PAM IHC HER2+ve tumours; HR<1% 82% HER2+ve by PAM IHC HER2+ve tumours; HR>10% 54% HER2+ve; 43% luminal A/B by PAM50 Cheang MCU, et al. The Oncologist 2015;20:
51 Defining molecular subtypes by quantitative receptor (HR) expression Conclusion: Significant discordance between IHC defined subsets and intrinsic molecular subtype determined by RT-qPCR For identifying basal-like subtype the optimal cut point for ER was <1% Tumours with borderline HR by IHC are molecularly diverse and may require additional assays Cheang MCU, et al. The Oncologist 2015;20:
52 What limits the use of IHC and gene expression profiling? The quality of the paraffin block Access and Cost IHC, ISH, molecular genetics are highly specific and reproducible testing methodologies using paraffin blocks The techniques fail when pre-analytical protocols are not in place The principles of strict QC and QA should be applied Carlson RW, et al. J Natl Compr Canc Netw 2006; 4:S1 S22; Wolff AC, et al. J Clin Oncol 2007; 25:
53 Quality control and quality assurance? Quality control Achieving and/or maintaining the desired level of quality Inspecting samples at each step and assessing what changes may be needed Internal validation of procedures Performed on each batch Guarantees the accuracy of every test BY THE TESTING LABORATORY Quality assurance Aims to improve overall performance of testing Compares performance with other centres BY AN EXTERNAL LABORATORY
54 Strategies for best test performance, interpretation and reporting (best practice) Standardised and recommended practice Monitor and maintain quality (quality system) Test accuracy and reproducibility
55 Quality Control Starts in the Operating Theatre with handling and fixation
56 Why Is Fixation So Important? Aims of Fixation: To prevent autolysis or decomposition To preserve tissue as near to its original form as possible To protect tissue against subsequent changes during processing & embedding Essentials For Good Fixation: Fresh tissue Proper penetration of fixative Right choice of a correctly prepared fixative
57 Specimen Handling Slicing of Excision Specimens Surgical specimens should be sliced into 5-10mm slices to ensure rapid and even fixation Fixative will not penetrate tissue thicker than 10mm
58 Why 10% Neutral Buffered Formalin? Lots of Reasons! Clinically validated for HER2 testing Use of any other fixative will require validation by the lab FDA kit Requirement; otherwise invalidates test/assay Other fixatives shown to produce inconsistent results Alcohol/acetone decrease quality of IHC/ ISH Bouin s decreases preservation of many anitgens Bouin s causes autofluorescence with ISH
59 Fixative Formulation - 10% NBF (ph 7.0) 10% NBF solution Formalin (40% formaldehyde) Sodium dihydrogen phosphate monohydrate Disodium hydrogen phosphate (anhydrous) Distilled water 100 ml 4.0 g 6.5 g 900 ml Termed 10% NBF but is actually 4% solution of formaldehyde
60 Standardisation Of Fixation Formula for Fixative = Step 1 of standardisation Step 2 = Quality Step 3 = Volume Step 4 = Time
61 Quality Step 2 = Quality - Commercial vs Home Made use fresh solution DO NOT RE-USE Quality
62 Volume Step 3 = Volume - size of tissue being fixed: - minimum 10:1 ratio - fixative to tissue Container Must Be of Adequate Size for the Tissue Image from:
63 Time Step 4 = Time - duration of fixation fixation penetration Published guidelines Wolff et al, J Clin Oncol 2007;26 and October2013 Walker et al, J Clin Pathol 2008;61: Ruschoff et al, Mod Pathol 2012;25: hours minimum for breast biopsies 8 hours minimum for gastric biopsies hours for breast and gastric surgical excisions
64 Summary Do s and Don ts! Ensure proper fixation and handling in the Operating Theatre Slice the specimen on receipt in the Laboratory Use validated protocols and quality control measures at all intralaboratory processes Report traditional pathology features and biomarker results following published guidelines If using Ki-67 ensure that the technique used and threshold are validated Talk to members of the multidisciplinary team formally at meetings and informally to explain: problematic/unusual/unexpected results Don t issue a pathology report if you are uncertain of its accuracy consult with a pathologist with more experience Don t leave preparation of reagents to junior members of staff without supervision Don t leave pathology residents in the grossing room without access to a pathologist for guidance Don t report a difficult case on Friday evening if it can wait until Monday morning!
65 Key Points In addition to standard pathology reporting, oncologists are wanting more information, specifically related to proliferation rate and to intrinsic molecular subtypes, which can predict response to therapy Molecular testing is expensive and may not be accessible to all breast cancer patients Using IHC-determined ER/PR/HER2 and Ki67 can assist in categorising cancers into molecular subtypes Attention to pre-analytical and post-analytical processes is crucial to success with all these tests The correlation between IHC results and molecular subtypes assessed by RT-qPCR is imprecise and results should be applied with caution HER2, human epidermal growth receptor 2; QA, quality assurance procedures; QC, quality control.
66
Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationFISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC
Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have
More informationA new way of looking at breast cancer tumour biology
A new way of looking at breast cancer tumour biology Contents Intrinsic subtypes of breast cancer 3 Gene expression assays 3 Basis of the Prosigna test 4 Information provided by Prosigna 5 The accuracy
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationDiagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Pathology Pathology Versions 2004 2017: Blohmer / Costa / Fehm / Friedrichs / Huober / Kreipe / Lück / Schneeweis / Sinn /
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationProfili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI
Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo BREAST CANCER Brain Adjuvant Medical Therapies
More informationGOALS AND OBJECTIVES BREAST PATHOLOGY
GOALS AND OBJECTIVES BREAST PATHOLOGY LEVEL: PGY2, PGY3, PGY5 A number of these rotations are introductory in nature, as they are major subspecialties, and are followed by two more blocks in PGY-3, during
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationThe Oncotype DX Assay A Genomic Approach to Breast Cancer
The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationQuality Assurance and Quality Control in the Pathology Dept.
Quality Assurance and Quality Control in the Pathology Dept. Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 2 nd IBDC, 9 th February, 2012 Pathology as
More informationOverview of AJCC 8 th Staging in Pathologic Aspects
Overview of AJCC 8 th Staging in Pathologic Aspects Jee Yeon KIM, M.D.,Ph.D. Department of Pathology, Pusan National University, College of Medicine, Pusan National University Yangsan Hospital, KOREA Major
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationQuality assurance and quality control in pathology in breast disease centers
Quality assurance and quality control in pathology in breast disease centers Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 1 st IBDC, 28 th January, 2011
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationPost Neoadjuvant therapy: issues in interpretation
Post Neoadjuvant therapy: issues in interpretation Disclosure: Overview D Prognostic features in assessment of post treatment specimens: Tumor size Cellularity Grade Receptors LN Neoadjuvant chemotherapy:
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationModern classification of breast cancer-should we stick with morphology or convert to molecular profiles?
Modern classification of breast cancer-should we stick with morphology or convert to molecular profiles? Ian Ellis Professor of Cancer Pathology Molecular Medical Sciences University of Nottingham Dept
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationGene Expression Profiling for Managing Breast Cancer Treatment. Policy Specific Section: Medical Necessity and Investigational / Experimental
Medical Policy Gene Expression Profiling for Managing Breast Cancer Treatment Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:
More informationBREAST CANCER PATHOLOGY
BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know
More informationEvaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy
Evaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy Eun Yoon Cho, MD, PhD Department of Pathology and Translational Genomics Samsung Medical Center Sungkyunkwan University
More informationType: Evidence Based Evidence Quality: High Strength of Recommendation: Strong
Clinical Question 1: For women with early-stage invasive breast cancer and with known estrogen and progesterone receptor (ER/PgR) and human epidermal growth factor receptor 2 (HER2 status), which other
More informationOptimal algorithm for HER2 testing
Optimal algorithm for HER2 testing The revised definition of IHC 2+ (equivocal) is invasive breast cancer with Weak to moderate complete membrane staining observed in >10% of tumor cells. (see Figure 1
More informationPROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT
PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT Author: Dr Sally Ann Hales On behalf of the Breast and pathology CNGs Written: March 2005 Reviewed by CNG: June 2009 &
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationBreast cancer classification: beyond the intrinsic molecular subtypes
Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationProblems in staging breast carcinoma
Problems in staging breast carcinoma Primary systemic therapy (PST) of breast carcinoma pathologists tasks Dr. Janina Kulka, 2nd Department of Pathology, Semmelweis University Budapest Austro-Hungarian
More informationLearning Objectives. Financial Disclosure. Breast Cancer Quality Improvement Project with Oncotype DX. Nothing to disclose
Breast Cancer Quality Improvement Project with Oncotype DX Denise Johnson Miller, MD, FACS Medical Director Breast Surgery Hackensack Meridian Health Legacy Meridian (Jersey Shore University Medical Center,
More informationXXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology
XXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology NUEVOS FENOTIPOS DEL CÁNCER DE MAMA: NUEVOS PROBLEMAS PARA EL PATÓLOGO? Tienen actualmente
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationI test molecolari nei protocolli di diagnosi e di trattamento
I test molecolari nei protocolli di diagnosi e di trattamento Anna Sapino IRCCs Candiolo Dip Scienze Mediche, Università degli Studi di Torino 2016: Pathological report of breast cancer MINIMAL REQUIREMENTS
More informationPapillary Lesions of the Breast
Papillary Lesions of the Breast Laura C. Collins, M.D. Associate Professor of Pathology Associate Director, Division of Anatomic Pathology Beth Israel Deaconess Medical Center and Harvard Medical School
More informationA712(19)- Test slide, Breast cancer tissues with corresponding normal tissues
A712(19)- Test slide, Breast cancer tissues with corresponding normal tissues (formalin fixed) For research use only Specifications: No. of cases: 12 Tissue type: Breast cancer tissues with corresponding
More informationBreast cancer staging update. Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director
Breast cancer staging update Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director 1 1 Review of the AJCC 8 th edition breast cancer staging Review of genomic assays as stage modifiers
More informationYour Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:
Your Guide to the Breast Cancer Pathology Report Key Questions Here are important questions to be sure you understand, with your doctor s help: Your Guide to the Breast Cancer Pathology Report 1. Is this
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationRelevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón
Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón Universidad Complutense Madrid The new technologies
More informationA712(18)- Test slide, Breast cancer tissues with corresponding normal tissues
A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues (formalin fixed) For research use only Specifications: No. of cases: 12 Tissue type: Breast cancer tissues with corresponding
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationAspects of quality in breast pathology. Andrew Lee Nottingham University Hospitals
Aspects of quality in breast pathology Andrew Lee Nottingham University Hospitals British breast pathology EQA: performance issues Ian Ellis Friday 8.30 am National breast screening pathology audit 2015
More informationPathology Report Patient Companion Guide
Pathology Report Patient Companion Guide Breast Cancer - Understanding Your Pathology Report Pathology Reports can be overwhelming. They contain scientific terms that are unfamiliar and might be a bit
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationBreast Cancer Assays of Genetic Expression in Tumor Tissue
Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/16/2016
More informationImmunohistochemistry on Fluid Specimens: Technical Considerations
Immunohistochemistry on Fluid Specimens: Technical Considerations Blake Gilks Dept of Pathology University of British Columbia, Vancouver, BC, Canada Disclosures None Learning Objectives At the end of
More informationBreast Cancer Diversity Various Disease Subtypes Clinical Diversity
Breast Cancer Predictive Factor Testing: The Challenge and Importance of Standardizing Pre- Analytic Variables David G. Hicks MD Professor of Pathology & Laboratory Medicine Director of Surgical Pathology
More informationNEUROENDOCRINE DIFFERENTIATED BREAST CARCINOMA
+ NEUROENDOCRINE DIFFERENTIATED BREAST CARCINOMA + INTRODUCTION + NEUROENDOCRINE FEATURES IN BREAST CARCINOMA Incidence of 2-5% Seen in various histopathological types of breast carcinoma Seen in both
More informationAssays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
Medical Policy Manual Genetic Testing, Policy No. 42 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Next Review: December 2018 Last Review:
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationPapillary Lesions of the Breast: WHO Update
Papillary Lesions of the Breast: WHO Update Stuart J. Schnitt, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA Papillary Lesions of the Breast
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationMammaPrint, the story of the 70-gene profile
MammaPrint, the story of the 70-gene profile René Bernards Professor of Molecular Carcinogenesis The Netherlands Cancer Institute Amsterdam Chief Scientific Officer Agendia Amsterdam The breast cancer
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationOVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER
OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER Aleix Prat, MD PhD Medical Oncology Department Hospital Clínic of Barcelona University of Barcelona esmo.org Disclosures Advisory role for
More informationBreast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
More information# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer
#1034 - Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer Richard W. Cartun, MS, PhD Andrew Ricci, Jr, MD Department of Pathology Hartford
More informationPrognostic and Predictive Factors
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Prognostic and Predictive Factors Prognostic and Predictive Factors Version 2002: Thomssen / Harbeck Version 2003 2009: Costa
More informationDisclosures 5/27/2012. Outline of Talk. Outline of Talk. When Is LCIS Clinically Significant? Classic LCIS. Classic LCIS
When Is LCIS Clinically Significant? Disclosures I have nothing to disclose Yunn-Yi Chen, MD, PhD Professor Outline of Talk Outline of Talk Classic LCIS Classic LCIS Definition of lobular differentiation
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationCase Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationDuctal Carcinoma in Situ. Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA
Ductal Carcinoma in Situ Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Definition of DCIS WHO 2012 A neoplastic proliferation
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Breast Cancer. Pathologic Staging Updates Breast Cancer
Pathologic Staging Updates in Breast Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More information1. Guidelines for Reporting Carcinoma of the Breast
1 2 1. Guidelines for Reporting Carcinoma of the Breast Compilation and editing of this volume: Prof. Dilani Lokuhetty (Consultant Histopathologist) List of contributors Consultant Histopathologists Dr.
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationImmunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology
SMGr up Immunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology Bhanumathi K Rao 1 * 1 Department of Biochemistry, JSS Medical College, a constituent
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationPrognostic implications of the intrinsic molecular subtypes in male breast cancer
JBUON 2017; 22(2): 377-382 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Prognostic implications of the intrinsic molecular subtypes in male
More informationBreast cancer pathology
Breast cancer pathology Giancarlo Pruneri, M.D. National Cancer Institute (INT) Milan University of Milan, School of Medicine Giancarlo.Pruneri@unimi.it Currently accepted prognostic/predictive parameters
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationPapillary Lesions of the breast
Papillary Lesions of the breast Emad Rakha Professor of Breast Pathology The University of Nottingham Papillary lesions of the breast are a heterogeneous group of disease, which are characterised by neoplastic
More informationVersion 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-
Introduction: These guidelines represent systematically developed statements to assist in the provision of quality assured HER2 testing in breast and gastric/ gastro-oesophageal carcinoma. They are based
More informationComparison of Triple Negative Breast Cancer between Asian and Western Data Sets
2010 IEEE International Conference on Bioinformatics and Biomedicine Workshops Comparison of Triple Negative Breast Cancer between Asian and Western Data Sets Lee H. Chen Bioinformatics and Biostatistics
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationMorphological and Molecular Typing of breast Cancer
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationSection: Genetic Testing Last Reviewed Date: March Policy No: 42 Effective Date: June 1, 2014
Medical Policy Manual Topic: Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer Date of Origin: October 5, 2004 Section: Genetic Testing Last
More informationLow ER+ Breast Cancer. Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD ABSTRACT
Low ER+ Breast Cancer Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD From the Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA.
More informationBradley M Turner MD, MPH, MHA. Assistant Professor University of Rochester Department of Pathology and Laboratory Medicine
Bradley M Turner MD, MPH, MHA Assistant Professor University of Rochester Department of Pathology and Laboratory Medicine My real job!!! I have nothing to disclose although Oncotype Dx year end revenues
More informationBreast Cancer Assays of Genetic Expression in Tumor Tissue
Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/02/2008 Line(s) of Business: Current Effective Date Section: 05/25/2018 Other Miscellaneous
More information